Quirem Medical B.V.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Quirem Medical B.V.
Padagis has added fresh competition on Narcan in the US, with its nasal naloxone spray introduced to the market as part of a trio of launches that also includes adapalene gel and betamethasone ointment.
US FDA inspections lead to warning letters for Aurobindo and Health Plus, while Emergent BioSolutions site escapes nearly unscathed; Sun waits for Halol revisit and Jubilant suffers poor-quality costs as agency investigators resume domestic surveillance post-omicron.
Less than six months into life as an independent company, former Perrigo Rx unit Padagis has realized its second generic launch, with the first-to-market entry of generic Zomig (zolmitriptan) nasal spray.
Health technology assessment body NICE has now recommended that selective internal radiation therapy can be used on England’s National Health Service for treating advanced liver cancer.
- Diagnostic Imaging Equipment & Supplies